Related references
Note: Only part of the references are listed.The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery
Marieke Timmermans et al.
MINERVA ENDOCRINOLOGY (2022)
Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort
Sky Graybill et al.
ANDROLOGY (2021)
Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility?
Rossella Cannarella et al.
ANDROLOGY (2021)
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial
Susanne Tan et al.
DIABETES OBESITY & METABOLISM (2021)
Obesity and GLP-1
Alejandra Perez-Montes De Oca et al.
MINERVA ENDOCRINOLOGY (2021)
Macrovascular Complications of Type 2 Diabetes Mellitus
Margus Viigimaa et al.
CURRENT VASCULAR PHARMACOLOGY (2020)
Sitagliptin protects male albino rats with testicular ischaemia/reperfusion damage: Modulation of VCAM-1 and VEGF-A
Asmaa Mohamed Abdel-Aziz et al.
ANDROLOGIA (2020)
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
Sin-Hee Park et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men
Chioma Izzi-Engbeaya et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism
Vito Angelo Giagulli et al.
ANDROLOGY (2020)
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Angelica Artasensi et al.
MOLECULES (2020)
Glucagon-like peptide-1 receptor is expressed in human and rodent testis
Rosario Caltabiano et al.
ANDROLOGY (2020)
New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide An update for endocrinologists and nutritionists
Luigi Barrea et al.
MINERVA ENDOCRINOLOGICA (2020)
Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome
Delbar Daneshjou et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now
Michael E. Johansen et al.
CLINICAL CARDIOLOGY (2020)
Effects of liraglutide on obesity-associated functional hypogonadism in men
M. Jensterle et al.
ENDOCRINE CONNECTIONS (2019)
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
Emily Brown et al.
OBESITY REVIEWS (2019)
Effects of quercetin, sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats
Zheen Aorahman Ahmed et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes A meta-analysis
Cai-Yan Zou et al.
MEDICINE (2019)
Diabetes-induced hyperglycemia impairs male reproductive function: a systematic review
Constanze C. Maresch et al.
HUMAN REPRODUCTION UPDATE (2018)
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity
N. Shao et al.
ANDROLOGIA (2018)
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
Dustin M. Lee et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Hypogonadotropic Hypogonadism in Men With Diabesity
Sandeep Dhindsa et al.
DIABETES CARE (2018)
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
Thomas Danne et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes
Rana Assaly et al.
JOURNAL OF SEXUAL MEDICINE (2018)
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Daniel S. Hsia et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome
Themistoklis Tzotzas et al.
CURRENT VASCULAR PHARMACOLOGY (2017)
GLP-1 increases Kiss-1 mRNA expression in kisspeptin-expressing neuronal cells
Aki Oride et al.
BIOLOGY OF REPRODUCTION (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways
Imre Farkas et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
GLP-1 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice
Erhong Zhang et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2015)
GLP1, an Important Regulator of Intestinal Lipid Metabolism
Geesje M. Dallinga-Thie et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
GLP-1 Increases Preovulatory LH Source and the Number of Mature Follicles, As Well As Synchronizing the Onset of Puberty in Female Rats
Veronica Outeirino-Iglesias et al.
ENDOCRINOLOGY (2015)
Impaired expression of sex hormone receptors in male reproductive organs of diabetic rat in response to oral antidiabetic drugs
Nasra N. Ayuob et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2015)
DPP-4 inhibition improves a sexual condition?
V. Altabas et al.
MEDICAL HYPOTHESES (2015)
Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism
V. A. Giagulli et al.
ANDROLOGY (2015)
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Mojca Jensterle Sever et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
The effects of liraglutide on male fertility: a case report
Paula Fontoura et al.
REPRODUCTIVE BIOMEDICINE ONLINE (2014)
SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE
J. Cuypers et al.
ACTA CLINICA BELGICA (2013)
The Significance of Low Testosterone Levels in Obese Men
Carla Pelusi et al.
CURRENT OBESITY REPORTS (2012)
Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
Mark Fineman et al.
CLINICAL PHARMACOKINETICS (2011)
DPP-IV inhibitor may affect spermatogenesis
Hatsuki Hibi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Samer El-Kaissi et al.
CURRENT DIABETES REVIEWS (2011)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome
Karen Elkind-Hirsch et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Kisspeptin and KISS1R: a critical pathway in the reproductive system
Elena Gianetti et al.
REPRODUCTION (2008)
Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males
A Jeibmann et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
